Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | GBA1 | P04062 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11337025 | 1.00 | FUCA1 (0.58) | FUCA1SIGMAR1S1PR1S1PR5DRD2 | |
| SCHEMBL11337029 | 1.00 | FUCA1 (0.58) | FUCA1SIGMAR1S1PR1S1PR5DRD2 | |
| Oxalic Acid SCHEMBL10839785 | 0.91 | S1PR5 (0.55) | FUCA1SIGMAR1S1PR1S1PR5GBA1 | |
| SCHEMBL2180441 | 0.87 | ACHE (0.54) | SIGMAR1DRD2DRD3ALDH1A1ACHE | |
| SCHEMBL21812106 | 0.86 | SIGMAR1 (0.50) | FUCA1SIGMAR1ALDH1A1ACHECYP1A2 | |
| SCHEMBL16908647 | 0.85 | FUCA1 (0.51) | FUCA1SIGMAR1S1PR1S1PR5DRD2 | |
| SCHEMBL10979574 | 0.82 | SIGMAR1 (0.55) | FUCA1SIGMAR1S1PR1S1PR5DRD2 | |
| SCHEMBL10980746 | 0.82 | SIGMAR1 (0.55) | FUCA1SIGMAR1S1PR1S1PR5DRD2 | |
| SCHEMBL3107774 | 0.82 | ALDH1A1 (0.52) | SIGMAR1S1PR5ALDH1A1TDP1ACHE | |
| SCHEMBL30881344 | 0.81 | FUCA1 (0.47) | FUCA1SIGMAR1S1PR1S1PR5DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4230718-A | CATARACT PREVENTION IN DIABETIC ANIMALS; CHEMICAL INTERMEDIATES | A. H. ROBINS COMPANY, INC. (US) | 1980-10-28 | — | — | US | claimed |
| CN-113307757-B | Preparation method of medical intermediate N-benzyl-3-pyrroline | 南京德克瑞医药化工有限公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3164403-B1 | TRICYCLIC TRIAZOLIC COMPOUNDS | ESTEVE LABOR DR (ES) | 2018-08-29 | — | — | EP | disclosed |
| US-10035805-B2 | Tricyclic triazolic compounds | ESTEVE PHARMACEUTECALS, S.A. (ES) | 2018-07-31 | — | — | US | disclosed |
| US-20170313710-A1 | TRICYCLIC TRIAZOLIC COMPOUNDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-11-02 | — | — | US | disclosed |
| EP-3164403-A1 | TRICYCLIC TRIAZOLIC COMPOUNDS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2017-05-10 | — | — | EP | disclosed |
| EP-2079727-B1 | KINASE INHIBITOR COMPOUNDS | XCOVERY INC (US) | 2016-02-17 | — | — | EP | disclosed |
| WO-2016001345-A1 | TRICYCLIC TRIAZOLIC COMPOUNDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-01-07 | — | — | WO | disclosed |
| EP-2963041-A1 | Tricyclic triazolic compounds | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2016-01-06 | — | — | EP | disclosed |
| US-8524709-B2 | Kinase inhibitor compounds | TYROGENEX, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-5416096-A | 7-(1-pyrrolidinyl)-3-quinolone carboxylic acid derivatives as antibacterial agents and feed additives | BAYER AKTIENGESELLSCHAFT (DE) | 1995-05-16 | — | — | US | disclosed |
| EP-0571400-A1 | NOVEL QUINOLONE COMPOUNDS AND PROCESSES FOR PREPARATION THEREOF | HANMI PHARMACEUTICAL CO.,LTD. (KR) | 1993-12-01 | — | — | EP | disclosed |
| WO-1992012155-A1 | NOVEL QUINOLONE COMPOUNDS AND PROCESSES FOR PREPARATION THEREOF | HANMI PHARMACEUTICAL CO., LTD. (KR) | 1992-07-23 | — | — | WO | disclosed |
| US-5059597-A | Animal growth regulators; enterobacter | BAYER AKTIENGESELLSCHAFT (DE) | 1991-10-22 | — | — | US | disclosed |
| US-4990517-A | 7-(1-pyrrolidinyl)-3-quinolone- and -naphthyridonecarboxylic acid derivatives as antibacterial agents and feed additives | BAYER AKTIENGESELLSCHAFT (DE) | 1991-02-05 | — | — | US | disclosed |
| EP-0350733-A2 | 7-(1-Pyrrolidinyl)-3-quinolone- and -naphthyridone-carboxylic-acid derivatives, method for their preparation and for substituted mono- and bi-cyclic pyrrolidine intermediates, and their antibacterial and feed additive compositions | BAYER AG (DE) | 1990-01-17 | — | — | EP | disclosed |
| US-4585785-A | HYPOTENSIVES, ANTIDEPRESSANTS | A. H. ROBINS COMPANY, INC. (US) | 1986-04-29 | — | — | US | disclosed |
| US-4452809-A | ANTIARRHYMIA, HYPOTENSIVE AGENTS | A. H. ROBINS COMPANY, INC. (US) | 1984-06-05 | — | — | US | disclosed |
| US-4254135-A | ANTIDEPRESSANT | A. H. ROBINS COMPANY, INC. (US) | 1981-03-03 | — | — | US | disclosed |
| US-4251541-A | ANTIDEPRESSANTS | A. H. ROBINS COMPANY, INC. (US) | 1981-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313710-A1 | TRICYCLIC TRIAZOLIC COMPOUNDS | SIGMAR1, OPRK1, OPRM1 | FUCA1 4543/4885SIGMAR1 1/4885S1PR1 502/4885 |
| US-10035805-B2 | Tricyclic triazolic compounds | SIGMAR1, OPRK1, OPRM1 | FUCA1 4543/4885SIGMAR1 1/4885S1PR1 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.